lamifiban (BioDeep_00000843705)
代谢物信息卡片
化学式: C24H28N4O6 (468.2008748)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CN(CCC1OCC(=O)O)C(=O)C(CC2=CC=C(C=C2)O)NC(=O)C3=CC=C(C=C3)C(=N)N
InChI: InChI=1S/C24H28N4O6/c25-22(26)16-3-5-17(6-4-16)23(32)27-20(13-15-1-7-18(29)8-2-15)24(33)28-11-9-19(10-12-28)34-14-21(30)31/h1-8,19-20,29H,9-14H2,(H3,25,26)(H,27,32)(H,30,31)/t20-/m0/s1
描述信息
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent
D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
D006401 - Hematologic Agents > D000925 - Anticoagulants
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Robert D McBane, Krzysztof Karnicki, Waldemar E Wysokinski. Platelet recruitment to venous stent thrombi.
Journal of thrombosis and thrombolysis.
2013 Nov; 36(4):442-7. doi:
10.1007/s11239-013-0924-x. [PMID: 23595514] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - Mony Frojmovic, Benoit Labarthe, Chantal Legrand. Inhibition and reversal of platelet aggregation by alphaIIbbeta3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban.
British journal of haematology.
2005 Nov; 131(3):348-55. doi:
10.1111/j.1365-2141.2005.05782.x. [PMID: 16225655] - NULL. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes.
Circulation.
2002 Jan; 105(3):316-21. doi:
10.1161/hc0302.102573. [PMID: 11804986] - J Hong, A Larsson, K N Ekdahl, G Elgue, R Larsson, B Nilsson. Contact between a polymer and whole blood: sequence of events leading to thrombin generation.
The Journal of laboratory and clinical medicine.
2001 Aug; 138(2):139-45. doi:
10.1067/mlc.2001.116486. [PMID: 11477381] - A Navdaev, D Dörmann, J M Clemetson, K J Clemetson. Echicetin, a GPIb-binding snake C-type lectin from Echis carinatus, also contains a binding site for IgMkappa responsible for platelet agglutination in plasma and inducing signal transduction.
Blood.
2001 Apr; 97(8):2333-41. doi:
10.1182/blood.v97.8.2333. [PMID: 11290595] - D J Moliterno. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee.
American heart journal.
2000 Apr; 139(4):563-6. doi:
10.1016/s0002-8703(00)90031-0. [PMID: 10740135] - S M Sloan, E B Brown, Q Liu, M M Frojmovic. Glycoprotein IIb-IIIa-liposomes bind fibrinogen but do not undergo fibrinogen-mediated aggregation.
Platelets.
2000 Mar; 11(2):99-110. doi:
10.1080/09537100075715. [PMID: 10938888] - G Stephens, N O'Luanaigh, D Reilly, P Harriott, B Walker, D Fitzgerald, N Moran. A sequence within the cytoplasmic tail of GpIIb independently activates platelet aggregation and thromboxane synthesis.
The Journal of biological chemistry.
1998 Aug; 273(32):20317-22. doi:
10.1074/jbc.273.32.20317. [PMID: 9685382] - G Lehne, K P Nordal, K Midtvedt, T Goggin, F Brosstad. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction.
Thrombosis and haemostasis.
1998 Jun; 79(6):1119-25. doi:
10.1055/s-0037-1615027. [PMID: 9657435] - R C Carroll, X F Wang, F Lanza, B Steiner, W C Kouns. Blocking platelet aggregation inhibits thromboxane A2 formation by low dose agonists but does not inhibit phosphorylation and activation of cytosolic phospholipase A2.
Thrombosis research.
1997 Oct; 88(2):109-25. doi:
10.1016/s0049-3848(97)00223-5. [PMID: 9361365]